FrancophonIA/ELRC3.0 huggingface dataset:
English: Truxima is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).
Maltese: Truxima huwa indikat għat-trattament ta' pazjenti b'pemphigus vulgaris (PV) moderat sa sever.
English: Initial treatment, in combination with chemotherapy In an open-label randomised trial, a total of 322 previously untreated patients with follicular lymphoma were randomised to receive either CVP chemotherapy (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for 8 cycles or rituximab 375 mg/m2 in combination with CVP (R-CVP).
Maltese: Fi prova klinika tat-tip open-label u randomised, total ta' 322 pazjent b'limfoma follikulari li ma kinux irċevew kura qabel ġew randomised biex jirċievu kimoterapija CVP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 sa massimu ta' 2 mg fl-ewwel jum, u prednisolone 40 mg/m2/jum mill-ewwel sal-ħames jum) kull 3 ġimgħat għal 8 ċikli jew rituximab 375 mg/m2 flimkien ma' CVP (R-CVP).
English: 48-months
Maltese: 49 sena
English: Psychiatric depression, anxiety
Maltese: Disturbi psikjatriċi depressjoni, ansjetà
English: The Physician information about Truxima should contain the following key elements:
Maltese: Informazzjoni għat-tabib dwar Truxima għandha tinkludi l-punti essenzjali li ġejjin:
English: Truxima works best in those who have a positive blood test to rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP).
Maltese: L-aħjar rispons għal Truxima huwa osservat f'dawk li jkollhom test tad-demm pożittiv għall-fattur rewmatiku (RF) u/jew għall-anti-Cyclic Citrullinated Peptide (anti-CCP).
English: Other medicines and Truxima
Maltese: Mediċini oħra u Truxima
English: When you are treated with Truxima in combination with chemotherapy, you will receive Truxima infusions on day 0 cycle 1 then day 1 of each cycle for 6 cycles in total.
Maltese: Meta tkun qed tiġi kkurat bi Truxima flimkien ma' kimoterapija, inti se tirċievi infużjonijiet ta' Truxima f'ġurnata 0 ta' ċiklu 1 u wara f'ġurnata 1 ta' kull ċiklu għal total ta' 6 ċikli.
English: Available data suggest that clinical response is usually achieved within 16 - 24 weeks of an initial treatment course.
Maltese: Id-dejta disponibbli tissuġġerixxi li r-rispons kliniku normalment jintlaħaq fi żmien 16-24 ġimgħa wara kors ta' kura inizjali.
English: • allergic reactions that are most likely to occur during an infusion, but can occur up to 24-hours after infusion
Maltese: • reazzjonijiet allerġiċi li huma l-aktar probabbli li jseħħu matul infużjoni, iżda jistgħu jseħħu sa 24 siegħa wara infużjoni
English: d) Granulomatosis with polyangiitis or microscopic polyangiitis
Maltese: d) Granulomatosi b'polianġite jew polianġite mikroskopika
English: • skin reactions including hives, itching and rash
Maltese: • reazzjonijiet fil-ġilda inkluż ħorriqija, ħakk u raxx
English: The prepared infusion solution of rituximab in 0.9% sodium chloride solution is physically and chemically stable for 30 days at 2 °C - 8 °C and subsequently 24 hours at room temperature (not more than 30 °C).
Maltese: Prodott dilwit Is-soluzzjoni għal infużjoni mħejjija ta' rituximab f'soluzzjoni ta' 0.9% sodium chloride hija fiżikament u kimikament stabbli għal 30 ijiem f'temperatura ta' 2 °C - 8°C u sussegwentement għal
English: Cases of posterior reversible encephalopathy syndrome (PRES) / reversible posterior leukoencephalopathy syndrome (RPLS) have been reported.
Maltese: Kienu rrappurtati każijiet ta' sindrome ta' enċefalopatija posterjuri riversibbli (PRES - posterior reversible encephalopathy syndrome) sindrome ta' lewkoenċefalopatija riversibbli posterjuri (RPLSreversible posterior leukoencephalopathy).
English: severe vision loss5
Maltese: konġuntivite telf sever talvista5
English: Truxima in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.
Maltese: Truxima flimkien ma' methotrexate huwa indikat għall-kura ta' pazjenti adulti b'artrite rewmatika attiva severa li kellhom rispons inadegwat jew intolleranza għal mediċini anti-rewmatiċi oħra li jimmodifikaw il-marda (DMARD) fosthom terapija ta' inibizzjoni waħda jew aktar tal-fattur tannekrosi tat-tumuri (TNF).
English: Do not have Truxima if you have an active infection or a serious problem with your immune system.
Maltese: Tiħux Truxima jekk ikollok infezzjoni attiva jew problema serja bis-sistema immuni tiegħek.
English: Truxima 500 mg concentrate for solution for infusion
Maltese: Truxima 500 mg konċentrat għal soluzzjoni għal infużjoni
English: conjunctivitis
Maltese: RESPONSABBLI
English: Rarely Truxima can cause a serious brain infection, called “Progressive Multifocal Leukoencephalopathy” or PML.
Maltese: B'mod rari Truxima jista' jikkawża infezzjoni serja fil-moħħ, imsejħa “lewkoenċefalopatija multifokali progressiva” jew PML.
English: Figure 2: ACR responses for 4 treatment courses (24 weeks after each course (within patient, within visit) in patients with an inadequate response to TNF-inhibitors (n=146)
Maltese: Rispons ACR għal 4 korsijiet ta' kura (24 ġimgħa wara kull kors (fil-pazjent, fil vista) f'pazjenti b'rispons mhux adegwat għall-inibituri ta' TNF (n = 146)
English: +left ventricular failure, +supraventricular tachycardia, +ventricular tachycardia, +angina, +myocardial ischaemia, bradycardia severe cardiac disorders4
Maltese: +insuffiċjenza ventrikulari tax-xellug, +takikardja supraventrikula ri, +takikardja ventrikulari,
English: Truxima 100 mg concentrate for solution for infusion
Maltese: Truxima 100 mg konċentrat għal soluzzjoni għal infużjoni
English: Repeated treatment courses with Truxima are possible.
Maltese: Mhux rakkomandat tnaqqis fid-doża ta' Truxima.
English: Truxima is provided in sterile, preservative-free, non-pyrogenic, single use vials.
Maltese: Truxima jiġi fornut f'kunjetti sterili, mingħajr preservattivi, mhux piroġeniċi, li jintużaw darba biss.
English: Ear and labyrinth tinnitus, ear pain hearing loss5
Maltese: newropatija kranjali, telf ta' sensi oħra5
English: • inflammation, irritation and / or tightness of the lungs and throat, coughing
Maltese: • infjammazzjoni, irritazzjoni u/jew tgħafis fil-pulmun, u ġriżmejn, sogħla
English: reached p < 0.0001
Maltese: Ma ntlaħaqx p < 0.0001
English: Repeated courses of treatment with Truxima are possible.
Maltese: Korsijiet ripetuti ta' kura bi Truxima huma possibbli.
English: For CLL patients whose lymphocyte counts are > 25 x 109/L it is recommended to administer prednisone/prednisolone 100 mg intravenous shortly before infusion with Truxima to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome.
Maltese: 100 mg prednisone/prednisolone fil-vina eżatt qabel infużjoni b'rituximab biex jitnaqqsu r- rata u s severità ta' reazzjonijiet akuti għall-infużjoni u/jew is-sindrome tar-reħa taċ-ċitokina.
English: Kaplan-Meier Estimate of Median Time to Event (months)
Maltese: Estimu Kaplan-Meier ta' żmien medjan sal avveniment (xhur)
English: This syndrome may be associated with some features of tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphataemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death.
Maltese: Din is sindrome tista' tiġi assoċjata ma' xi karatteristiċi tas-sindrome tal-lisi tat-tumur bħall-iperuriċemija, iperkalimja, ipokalċimja, iperfosfatimja, insuffiċjenza akuta tal-kliewi, lactate dehydrogenase (LDH) elevat u tista' tkun assoċjata ma' kollass respiratorju akut u mewt.
English: Only
Maltese: JIS
English: In patients with granulomatosis with polyangiitis or microscopic polyangiitis, the number of peripheral blood B cells decreased to < 10 cells/μL after two weekly infusions of rituximab 375 mg/m2, and remained at that level in most patients up to the 6 month time point.
Maltese: F'pazjenti bi granulomatosi b'polianġite jew polianġite mikroskopika, in-numru ta' ċelluli B fid-demm periferali naqas għal < 10 ċelluli/μL wara infużjonijiet ta' rituximab 375 mg/m2 kull ġimagħtejn u fil-biċca l-kbira tal-pazjenti baqa' f'dan il-livell sa 6 xhur.
English: The MAH must ensure that all physicians who are expected to prescribe Truxima are provided with the following:
Maltese: Informazzjoni għall-pazjent dwar Truxima għandha tinkludi l-punti essenzjali li ġejjin:
English: Chronic lymphocytic leukaemia
Maltese: +tromboċitope nija anemija,
English: Cardiac disorders angina pectoris, atrial fibrillation, heart failure, myocardial infarction atrial flutter
Maltese: Disturbi fil-qalb anġina pectoris, fibrillazzjoni atrijali,
English: +left ventricular failure, +supraventricular tachycardia, +ventricular tachycardia, +angina, +myocardial ischaemia, bradycardia severe cardiac disorders4 and 6
Maltese: +iskemija mijokardijaka, bradikardja disturbi kardijaċi severi 4 u 6
English: The safety and efficacy of Truxima in children below 18 years has not been established.
Maltese: Is-sigurtà u l-effikaċja ta' Truxima fi tfal taħt 18-il sena ma ġewx stabbiliti.
English: In patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis, methylprednisolone given intravenously for 1 to 3 days at a dose of 1000 mg per day is recommended prior to the first infusion of Truxima (the last dose of methylprednisolone may be given on the same day as the first infusion of Truxima).
Maltese: F'pazjenti bi granulomatosi b'polianġite (ta' Wegener) jew polianġite mikroskopika, methylprednisolone mogħti fil-vini għal 1 sa 3 ijiem b'doża ta' 1000 mg kuljum huwa rakkomandat qabel l-ewwel infużjoni ta' Truxima (l-aħħar doża ta' methylprednisolone tista' tingħata fl-istess jum bħall-ewwel infużjoni ta' Truxima).
English: Truxima maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
Maltese: Perċentwal ta' Pazjenti bl-Ewwel Irkadar Maġġuri effikaċja fil-prova klinika dwar terapija ta' manteniment.
English: You will always be given Truxima as a drip (intravenous infusion).
Maltese: Inti dejjem se tingħata Truxima bħala dripp (infużjoni fil-vini).
English: The recommended dosage of Truxima for induction of remission therapy of granulomatosis with polyangiitis and microscopic polyangiitis is 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks (four infusions in total).
Maltese: Id-dożaġġ rakkomandat ta' Truxima għal terapija għall-induzzjoni ta' remissjoni ta' granulomatosi b'polianġite u polianġite mikroskopika hija ta' 375 mg/m2 tal-erja tas-superfiċje tal-ġisem, mogħti bħala infużjoni fil-vini darba fil-ġimgħa għal 4 ġimgħat (total ta' erba' infużjonijiet).
English: Rituximab was administered as an intravenous infusion at a first-cycle dose of 375 mg/m2 increased to 500 mg/m2 each cycle for 5 doses in combination with fludarabine and cyclophosphamide in CLL patients.
Maltese: Rituximab kien mogħti f'dożaġġ ta' 375 mg/m2 waqt l-ewwel ċiklu ġurnata qabel il-kimoterapija u f'dożaġġ ta' 500 mg/m2 fl-ewwel ġurnata ta' kull ċiklu ta' kura sussegwenti.
English: The recommended dosage of Truxima for the treatment of pemphigus vulgaris is 1000 mg administered as an IV infusion followed two weeks later by a second 1000 mg IV infusion in combination with a tapering course of glucocorticoids.
Maltese: Id-dożaġġ rakkomandat ta' rituximab għat-trattament ta' pemphigus vulgaris huwa ta' 1,000 mg mogħti bħala infużjoni IV segwit ġimagħtejn wara mit-tieni infużjoni IV ta' 1,000 mg flimkien ma' kors ta' glukokortikojdi li jitnaqqsu għax-xejn.
English: Musculoskeletal and connective tissue disorders
Maltese: Disturbi Muskoluskeletriċi u tat-Tessuti
English: late neutropenia2 serum sickness-like reaction
Maltese: B'kuntrast mas-sindrome tar-reħa taċ-ċitokina,
English: Severe infusion-related reactions with fatal outcome have been reported during post-marketing use of the rituximab intravenous formulation, with an onset ranging within 30 minutes to 2 hours after starting the first rituximab intravenous infusion.
Maltese: Truxima inaqqas il-progressjoni tal-ħsara fil-ġogi tiegħek ikkawżata minn artrite rewmatika u jttejjeb il-ħila tiegħek li twettaq l-attivitajiet normali ta' kuljum.
English: Pierre Demolis (France)
Maltese: Pierre Demolis (Franza)
English: Tomas Salmonson (Sweden)
Maltese: Tomas Salmonson (Svezja)
English: 20 November 2008 Company responses provided on: 2 March 2009, 22 September 2009, 19 January 2010, 24 March
Maltese: 2 ta' Marzu 2009, 22 ta' Settembru 2009, 19 ta' Jannar 2010, 24 ta' Marzu 2010
English: Co-rapporteur(s):
Maltese: Korelatur(i):
English: Valtrex is also available in the EU under other trade names: Talavir, Valaciclovir Allen, Valaciclovir Biogaran, Valaciclovir GSK, Valaciclovir Sandoz, Valaciclovir Winthrop, Valavir, Valherpes, Valtrex S, Virval and Zelitrex.
Maltese: Valtrex huwa disponibbli wkoll fl-UE taħt ismijiet kumerċjali oħrajn: Talavir, Valaciclovir Allen, Valaciclovir Biogaran, Valaciclovir GSK, Valaciclovir Sandoz, Valaciclovir Winthrop, Valavir, Valherpes, Valtrex S, Virval u Zelitrex.
English: What is Valtrex?
Maltese: X'inhu Valtrex?
English: Valtrex is an antiviral medicine that contains the active substance valaciclovir.
Maltese: Valtrex huwa prodott mediċinali antivirali li fih is-sustanza attiva valaciclovir.
English: • HSV infections of the skin and mucous membranes including: the treatment of the first episode of genital herpes in immunocompetent patients; the treatment of recurrent episodes of genital herpes in immunocompetent and immunocompromised patients (patients with a weakened immune system); the suppression of the recurrence of genital herpes in immunocompetent and immunocompromised patients; treatment of herpes labialis (cold sores); the treatment and suppression of recurrent ocular (eye) HSV infection;
Maltese: • infezzjonijiet ta' HSV tal-ġilda u membrani mukużi inklużi: il-kura tal-ewwel episodju ta' ħerpes ġenitali f'pazjenti immunokompetenti; il-kura ta' episodji rikorrenti ta' ħerpes ġenitali f'pazjenti immunokompetenti u pazjenti immunokompromessi (pazjenti b'sistema immunitarja mdgħajfa); it-trażżin tal-feġġa mill-ġdid ta' ħerpes ġenitali f'pazjenti immunokompetenti u immunokompromessi; il-kura ta' ħerpes labialis (ponot tad-deni); il-kura u trażżin ta' infezzjoni okulari (tal-għajnejn) ta' HSV;
English: Valtrex is also used to prevent infection with cytomegalovirus.
Maltese: Valtrex jintuża wkoll għall-prevenzjoni ta' infezzjoni minn cytomegalovirus.
English: • the prevention of cytomegalovirus infection and disease following solid organ transplantation in adults and adolescents.
Maltese: • il-prevenzjoni ta' infezzjoni u mard minn cytomegalovirus wara trapjant ta' organu solidu f'adulti u adoloxxenti.
English: 500 mg once a day for suppressing the recurrence of HSV infections in immunocompetent adults and 500 mg twice daily in immunocompromised adults.
Maltese: 500 mg darba kuljum għat-trażżin ta' rikorrenza ta' infezzjonijiet minn HSV f'adulti immunokompetenti u 500 mg darbtejn klujum f'adulti immunokompromessi.
English: The active substance in Valtrex, valaciclovir, is broken down in the body into two substances, aciclovir and valine (an amino-acid).
Maltese: Is-sustanza attiva f'Valtrex, valaciclovir, tinqasam fil-ġisem f'żewġ sustanzi, aciclovir u valine (li huwa aċidu-amminiku).
English: 13 July 2010
Maltese: 13 ta' Lulju 2010
English: Valtrex was authorised in the EU via national procedures.
Maltese: Valtrex ġie awtorizzat fl-UE permezz ta' proċeduri nazzjonali.
English: On 22 October 2008, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Valtrex and associated names in the EU.
Maltese: Fit-22 ta' Ottubru 2008, il-Kummissjoni Ewropea irriferiet il-kwistjoni lis-CHMP sabiex tarmonizza lawtorizzazzjonijiet għat-tqegħid fis-suq għal Valtrex u l-ismijiet assoċjati fl-UE.
English: Valtrex was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Maltese: Valtrex ġie identifikat bħala li għandu bżonn ta' armonizzazzjoni mill-Grupp ta' Koordinazzjoni dwar ilProċeduri Reċiproċi u Diċentralizzati - Għall-Bniedem (CMD(h)).
English: • For the treatment of herpes zoster, the recommended dose is 1000 mg three times a day for seven days in immunocompetent adults.
Maltese: • Għall-kura ta' ħerpes zoster, id-doża rrakkomandata hija ta' 1000 mg tliet darbiet kuljum għal sebat ijiem f'adulti immunokompetenti.
English: • For use in HSV infections of the skin and mucous membranes, the following doses are recommended: 500 mg twice a day for treating immunocompetent patients.
Maltese: • Għall-użu f'infezzjonijiet tal-ġilda u membrani mukużi, huma rrakkomandati d-dożi li ġejjin: 500 mg darbtejn kuljum f'pazjenti immunokompetenti.
English: • For the prevention of cytomegalovirus infection following organ transplantation in adults and adolescents, the recommended dosage is 2000 mg four times a day, to be started as early as possible after the transplant.
Maltese: • Għall-prevenzjoni ta' infezzjoni minn cytomegalovirus wara trapjant ta' organu f'adulti u adoloxxenti, id-dożaġġ irrakkomandat huwa ta' 2000 mg erba' darbiet kuljum, u għandu jinbeda kemm jista' jkun kmieni wara t-trapjant.
English: • the treatment of herpes zoster in adults with mild or moderate immunosuppression (reduced activity of the immune system);
Maltese: • il-kura ta' ħerpes zoster f'adulti b'immunosoppressjoni ħafifa jew moderata (attività nmaqqsa tassistema immunitarja);
English: Why was Valtrex reviewed?
Maltese: Għaliex ġie rivedut Valtrex?
English: The areas harmonised include: 4.1 Therapeutic indications The CHMP recommended that Valtrex should be used for:
Maltese: Is-sezzjonijiet armonizzati jinkludu: 4.1 Indikazzjonijiet terapewtiċi
English: • the treatment of herpes zoster (shingles) and ophthalmic zoster (shingles around the eye) in immunocompetent adults (patients with an immune system that works normally);
Maltese: • il-kura ta' ħerpes zoster (ħruq ta' Sant'Antnin) u zoster oftalmiku (ħruq ta' Sant-Antnin madwar lgħajn) f'adulti immunokompetenti (pazjenti li għandhom sistema immunitarja li taħdem b'mod normali);
English: Cytomegalovirus can cause harmful effects in high-risk populations such as infants and patients who have had a solid organ transplant.
Maltese: Is-cytomegalovirus jista' jikkawża effetti ħżiena f'popolazzjonijiet ta' riskju għoli bħal trabi u pazjenti li kellhom trapjant ta' organu solidu.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Valtrex in the European Union (EU).
Maltese: Il-Kumitat tal-Aġenzija għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) ikkonkluda li hemm bżonn ta' armonizzazzjoni tal-informazzjoni għall-preskrizzjoni għal Valtrex fl-Unjoni Ewropea (UE).
English: It is used to treat infections with herpes, including varicella zoster which causes shingles and herpes simplex viruses (HSV) which can cause cold sores or genital herpes.
Maltese: Din tintuża għall-kura ta' infezzjonijiet bil-ħerpes, inklużi varicella zoster li tikkawża l-ħruq ta' Sant-Antnin u virusijiet ta' ħerpes simplex (HSV) li jikkawżaw ponot tad-deni u ħerpes ġenitali.
English: The Committee also harmonised other sections of the SmPC, including the sections on special warnings and side effects.
Maltese: Il-Kumitat armonizza wkoll sezzjonijiet oħrajn tal-SmPC, inklużi s-sezzjonijiet bi twissijiet speċjali u effetti sekondarji.
English: Treatment should be evaluated after six to 12 months.
Maltese: Il-kura għandha tiġi evalwata wara sitt xhur sa 12-il xahar.
English: 4.2 Posology and method of administration The Committee harmonised the doses of Valtrex to be used for the different conditions.
Maltese: Il-Kumitat armonizza d-dożi ta' Valtrex li għandhom jintużaw għall-kundizzjonijiet differenti.
English: EMA/346237/2008 EMEA/V/C/000129
Maltese: EMEA/346237/2008 EMEA/V/C/000129
English: The full EPAR for Zactran can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Zactran gamithromycin
Maltese: Zactran gamitromiċin
English: In a study involving 364 sheep with typical signs of foot rot, 98% of Zactran-treated sheep were successfully treated after 3 weeks compared to 93% of tilmicosin-treated sheep based on lameness scores.
Maltese: Fi studju li involva 364 nagħġa b'sinjali tipiċi ta' necrobacillosis, 98% tan-nagħaġ ikkurati b'Zactran kienu kkurati b'suċċess wara 3 ġimgħat meta mqabbla ma' 93% tan-nagħaġ ikkurati b'tilmikosin ibbażati fuq livelli ta' zappip.
English: This is a summary of the European public assessment report (EPAR) for Zactran.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Zactran.
English: The active substance of Zactran, gamithromycin, is an antibiotic of the macrolide group.
Maltese: Is-sustanza attiva f'Zactran, il-gamitromiċin, hija antibijotiku tal-grupp tal-makrolidi.
English: Why is Zactran approved?
Maltese: Għaliex ġie approvat Zactran?
English: • swine respiratory disease (SRD), a lung infection in pigs, caused by Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Bordetella bronchiseptica;
Maltese: • mard respiratorju tal-ħnieżer (SRD), infezzjoni fil-pulmun fil-ħnieżer ikkawżata minn Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis u Bordetella bronchiseptica;
English: Zactran contains the active substance gamithromycin.
Maltese: Zactran fih is-sustanza attiva gamitromiċin.
English: Cattle weighing more than 250 kg, and pigs and sheep weighing more than 125 kg, will need to have the dose divided and injected at more than one site.
Maltese: Bhejjem tal-ifrat li jiżnu aktar minn 250kg, u ħnieżer u nagħaġ li jiżnu aktar minn 125 kg, se jkunu jeħtieġu li d-doża tinqasam u tiġi injettata f'aktar minn sit wieħed.
English: What are the risks associated with Zactran?
Maltese: X'inhuma r-riskji assoċjati ma' Zactran?
English: Zactran was shown to be effective in the treatment and metaphylaxis of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Maltese: Zactran deher li kien effettiv fil-kura u l-metafilassi tal-BRD assoċjati ma' Mannheimia haemolytica, Pasteurella multocida u Histophilus somni.
English: • bovine respiratory disease (BRD), a lung infection in cattle, caused by the bacteria Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Maltese: • mard respiratorju bovin (BRD), infezzjoni fil-pulmun f'bhejjem tal-ifrat ikkawżat mill-batterji Mannheimia haemolytica, Pasteurella multocida u Histophilus somni.
English: • foot rot in sheep caused by Dichelobacter nodosus and Fusobacterium necrophorum needing systemic treatment (treatment reaching the bacteria via the blood stream, e.g. by injection).
Maltese: • Necrobacillosis fin-nagħaġ ikkawżata minn Dichelobacter nodosus u Fusobacterium necrophorum li jkollhom bżonn kura sistemika (kura li tilħaq il-batterji permezz tad-demm, eż. b'injezzjoni).
English: Treatment success was 97% in the Zactran-treated pigs compared to 93% in the tildipirosin group.
Maltese: Il-kura rnexxiet b'97% fil-ħnieżer ikkurati b'Zactran meta mqabbla ma' 93% fil-grupp ta' tildipirosin.
English: It works by blocking the bacteria's ribosomes, which are parts of the cells where proteins are produced, and so prevents the bacteria from growing.
Maltese: Taħdem billi timblokka r-ribożomi tal-batterji, li huma partijiet taċ-ċelloli li fihom jiġu prodotti l-proteini, u b'hekk twaqqaf it-tkabbir tal-batterji.
English: For the treatment of SRD, a field study was conducted in pigs with SRD comparing Zactran to tildipirosin, another macrolide antibiotic.
Maltese: Għall-kura tal-SRD sar studju fuq il-post fil-ħnieżer bl-SRD li qabbel Zactran ma' tildipirosin, antibijotiku makrolidu ieħor.